KYTX
USDKyverna Therapeutics Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$6.670
高値
$6.930
安値
$6.670
出来高
0.31M
企業ファンダメンタルズ
時価総額
291.5M
業種
バイオテクノロジー
国
United States
取引統計
平均出来高
0.57M
取引所
NMS
通貨
USD
52週レンジ
関連ニュース
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $31
Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics with a Overweight and raises the price target from $27 to $31.
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $20
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Kyverna Therapeutics with a Buy and raises the price target from $10 to $20.
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
KYV-101 resulted in a profound reduction in disease-associated autoantibodies and impact on disease activity in patients with difficult-to-treat rheumatoid arthritis (RA) KYV-101 continues to demonstrate a
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases,
関連株式
最新情報を入手
価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。